National Cancer Institute, Division of Cancer Prevention, Rockville, MD, USA.
National Cancer Institute, Division of Cancer Prevention, Rockville, MD, USA.
Lancet Gastroenterol Hepatol. 2019 Feb;4(2):101-110. doi: 10.1016/S2468-1253(18)30358-3. Epub 2018 Nov 29.
Screening flexible sigmoidoscopy reduces incidence and mortality of colorectal cancer. Previously reported results from the Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) screening trial had a median follow-up of 12 years. Whether the benefit is sustained over the long term and remains so in both sexes and all age groups is uncertain. We report long-term results after an additional 5 years of follow-up.
Participants in the PLCO trial were recruited from the general population in the catchment areas of ten screening centres across the USA, without previous diagnosis of a prostate, lung, colorectal, or ovarian cancer or current cancer treatment. From 1993 to 2001, participants aged 55-74 years were randomly assigned to usual care or flexible sigmoidoscopy at baseline and again at 3 years or 5 years. Randomisation was done within blocks and stratified by centre, age, and sex. The primary endpoint was cause-specific mortality and secondary endpoints included incidence and tumour staging; cause of death was determined without knowledge of study arm. In this analysis, we assessed incidence and mortality rates overall, by time-period, and by combinations of sex, age at baseline (55-64 years/65-74 years), location (distal/proximal), and stage, on an intent-to-treat basis. This trial is registered with ClinicalTrials.gov, number NCT00002540.
After a median follow-up of 15·8 years (IQR 13·2-18·0) for incidence and 16·8 years (14·4-18·9) for mortality, the incidence of colorectal cancer was significantly lower in the intervention arm (1461 cases; 12·55 per 10 000 person-years) than with usual care (1761 cases; 15·33 per 10 000 person-years; relative risk [RR] 0·82, 95% CI 0·76-0·88). Similarly, mortality was lower in the intervention arm (417 deaths; 3·37 per 10 000 person-years) than the usual care arm (549; 4·48 per 10 000 person-years; RR 0·75, 95% CI 0·66-0·85). The reduction in mortality was limited to the distal colon, with no significant effect in the proximal colon. Reductions in incidence were significantly larger in men than women (p=0·04) and reductions in mortality were significantly larger in the older age group (65-74 years vs 55-64 years at baseline; p=0·01).
Reductions in colorectal cancer incidence and mortality from flexible sigmoidoscopy screening are sustained over the long term. Differences by sex and age should be examined in other ongoing trials of colorectal cancer screening to help clarify if different screening strategies would achieve greater risk reduction.
Extended follow-up was funded under NIH contract HHSN261201600007I.
筛查软性乙状结肠镜检查可降低结直肠癌的发病率和死亡率。之前来自前列腺癌、肺癌、结直肠癌和卵巢癌(PLCO)筛查试验的报告结果中位随访时间为 12 年。这种益处是否能长期持续,并且在男女和所有年龄组中都能持续存在,目前还不确定。我们报告了额外 5 年随访后的长期结果。
PLCO 试验的参与者是从美国十个筛查中心的覆盖人群中招募的,这些参与者没有前列腺癌、肺癌、结直肠癌或卵巢癌的既往诊断或当前的癌症治疗。从 1993 年到 2001 年,年龄在 55-74 岁的参与者在基线时和 3 年或 5 年后随机分配到常规护理或软性乙状结肠镜检查。随机化是在块内进行的,并按中心、年龄和性别分层。主要终点是特定原因的死亡率,次要终点包括发病率和肿瘤分期;死因是在不知道研究臂的情况下确定的。在这项分析中,我们基于意向治疗评估了总体发病率和死亡率,以及按时间阶段、性别、基线时的年龄(55-64 岁/65-74 岁)、位置(远端/近端)和阶段组合的发病率和死亡率。这项试验在 ClinicalTrials.gov 注册,编号为 NCT00002540。
在发病率的中位随访 15.8 年(IQR 13.2-18.0)和死亡率的中位随访 16.8 年(14.4-18.9)后,干预组的结直肠癌发病率明显低于常规护理组(1461 例;每 10000 人年 12.55 例)(1761 例;每 10000 人年 15.33 例;RR 0.82,95%CI 0.76-0.88)。同样,干预组的死亡率(417 例死亡;每 10000 人年 3.37 例)也低于常规护理组(549 例;每 10000 人年 4.48 例;RR 0.75,95%CI 0.66-0.85)。死亡率的降低仅限于远端结肠,近端结肠没有显著影响。男性的发病率降低幅度明显大于女性(p=0.04),而死亡率的降低幅度在年龄较大的年龄组(65-74 岁比基线时的 55-64 岁;p=0.01)中更为显著。
软性乙状结肠镜检查筛查结直肠癌的发病率和死亡率的降低可长期持续。在其他正在进行的结直肠癌筛查试验中,应根据性别和年龄进行差异分析,以帮助阐明不同的筛查策略是否能实现更大的风险降低。
延长随访是由美国国立卫生研究院合同 HHSN261201600007I 资助的。